DFMO Approved for PBS Listing

DFMO Approved for PBS Listing

Neuroblastoma Australia is pleased to announce that DFMO (IFINWIL/eflornithine) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS).

This important development is the final step in ensuring that children in Australia diagnosed with neuroblastoma have access to this potentially life-saving treatment. The positive PBAC recommendation means DFMO will now be administered locally and at minimal cost to families.

Until now, many families have faced the enormous emotional and financial burden of fundraising tens of thousands of dollars to travel overseas to access DFMO. The PBS listing means the treatment will be available here in Australia, easing the pressure on families and improving access to care.

This outcome is the result of tireless advocacy by families, politicians, researchers, and supporters across the country. Neuroblastoma Australia extends its deepest thanks to everyone who played a role in this effort. Your determination and collaboration have made a tangible difference in the lives of children affected by this devastating disease.

This is a tremendous achievement—and a testament to the power of collective action.